Preferred Label : fostamatinib;

MeSH note : a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406;

CISMeF synonym : R788 compound;

MeSH synonym : 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-;

MeSH hyponym : R 788 compound; 2H-pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, sodium salt (1:2); R935788 sodium anhydrous; R-935788 sodium anhydrous; R788 sodium anhydrous; R-788 sodium anhydrous; fostamatinib disodium salt hexahydrate; R-788 sodium; R788 sodium; R788 sodium hydrate; R-935788 sodium hydrate; R935788 sodium hydrate; fostamatinib disodium; (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl disodium phosphate hexahydrate; Tavalisse; R-788 sodium hydrate; R-935788 free acid; R935788 free acid; R-788 free acid;

MeSH Related Number : 86EEZ49YVB; X9417132K8;

Is substance : O;

UNII : SQ8A3S5101;

InChIKey : GKDRMWXFWHEQQT-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3226885/fr/tavlesse
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
fostamatinib
fostamatinib
fostamatinib
Syk Kinase
Tyrosine Kinase Inhibitor
protein kinase inhibitors
protein kinase inhibitors
adult
chronic disease
purpura, thrombocytopenic, idiopathic
Product containing only fostamatinib in oral dose form (medicinal product form)
guidelines for drug use
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
oxazines
pyridines
oxazines
pyridines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
fostamatinib
fostamatinib
fostamatinib
chronic disease
adult
purpura, thrombocytopenic, idiopathic
administration, oral
Syk Kinase
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
oxazines
pyridines
oxazines
pyridines

---
Nous contacter.
08/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.